Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment
Open accessThe DOI matches its Crossref record; 134 of the 135 references it cites were found in a registry or an index.
Abstract
Myeloid-derived suppressor cells (MDSC) are a diverse population of immature myeloid cells that have potent immune-suppressive activity. Studies in both mice and humans have demonstrated that MDSC accumulate in most individuals with cancer, where they promote tumor progression, inhibit antitumor immunity, and are an obstacle to many cancer immunotherapies. As a result, there has been intense interest in understanding the mechanisms and in situ conditions that regulate and sustain MDSC, and the mechanisms MDSC use to promote tumor progression. This article reviews the characterization of MDSC and how they are distinguished from neutrophils, describes the suppressive mechanisms used by MDSC to mediate their effects, and explains the role of proinflammatory mediators and the tumor microenvironment in driving MDSC accumulation, suppressive potency, and survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In preclinical models, both of these innate immune cell types aid tumor growth and metastasis through their secretion of factors that suppress antitumor immune responses, especially those of CD8 + T cells and NK cells (166, 167).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [166]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753 · cited 13×
“In contrast to STAT3, which promotes MDSC accumulation, IRF8 deters PMN-MDSC accumulation.”
BackgroundInfluentialCoordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Self-citationPolarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TAN
Fridlender, Z. G., Sun, J., Kim, S., Kapoor, V., Cheng, G., Ling, L., Worthen, G. S., & Albelda, S. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.017 · Cited by 3,371
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751 · cited 1×
“Because there has been considerable discussion about the nomenclature, phenotype, and function of this cell population, an international group of investigators in the field recently recommended nomenclature and characterization standards for MDSC (15).”
BackgroundSelf-citationThe Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.004 · Cited by 2,008
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Regulation of immune responses by L-arginine metabolism
Bronte, V., & Zanovello, P. (2005) · Nature Reviews Immunology · doi:10.1038/nri1668 · Cited by 1,775
Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Ostrand-Rosenberg, S., & Sinha, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802740 · Cited by 1,736 · cited 1×
“driving force for MDSC, and the hypothesis that one of the mechanisms by which inflammation drives cancer risk and tumor progression is through the suppression of antitumor immunity (47).”
Self-citationHuang, B., Pan, P.-Y., Li, Q., Sato, A. I., Levy, D. E., Bromberg, J., Divino, C. M., & Chen, S.-H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1299 · Cited by 1,435
Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,337
Research works printed but not linked: 1
- Geis-Asteggiante L 2017 Quantitative analysis of intact proteins and RNAs carried by immunosuppressive exosomes Ph.D. thesis University of Maryland
Cited by
Items 401–500 of 523
Basic cancer immunology for radiation oncologists
Sia, J., Neeson, P. J., & Haynes, N. M. (2022) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/1754-9485.13406 · Cited by 4
“Myeloid-derived suppressor cells play important tumourpromoting roles by their immunosuppressive function, mediated through cell-to-cell contact with Tand NK cells as well as via secretion of soluble mediators.(54) In addition, PMN-MDSCs together with neutrophils (the two subsets are often difficult to distinguish) ar…”
BackgroundZhou, L., Zhu, Y., Mo, L., Wang, M., Lin, J., Zhao, Y., Feng, Y., Xie, A., Wei, H., Qiu, H., et al. (2022) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0010851 · Cited by 3
Sharif, P. M., Khoshbin, A. P., Nasrollahzadeh, E., Keshavarz‐Fathi, M., & Rezaei, N. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-818006-8.00003-7 · Cited by 8
Chatterjee, P., & Banerjee, S. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115866 · Cited by 3
Pang, G., Chen, P., Cao, X., Yu, H., Zhang, L. W., Zhao, J., & Wang, F. (2023) · Biomaterials Science · doi:10.1039/d3bm01605f · Cited by 3
Huang, Z., Qian, C., Zhang, Z., Nian, W., Xu, Q., Cao, Y., & Fu, C. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116209 · Cited by 3
Borgna, E., Gamba, J. C., Prochetto, E., Marcipar, I. S., & Cabrera, G. (2024) · Methods in cell biology · doi:10.1016/bs.mcb.2024.01.001 · Cited by 3
Pak, V. N. (2022) · Cancer therapy & Oncology International Journal · doi:10.19080/ctoij.2022.20.556050 · Cited by 3
Battaglia, A., Buzzonetti, A., Fossati, M., Scambia, G., Fattorossi, A., Madiyalakan, M. R., Mahnke, Y. D., & Nicodemus, C. F. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02537-4 · Cited by 3
Welte, T., Mai, J., Zhang, Z., Tian, S., Zhang, G., Xu, Y., Zhang, L., Chen, S.-S., Wang, T., & Shen, H. (2021) · iScience · doi:10.1016/j.isci.2021.103349 · Cited by 2
“MDSCs also pose hurdles for cancer immunotherapy (Ostrand-Rosenberg and Fenselau, 2018).”
BackgroundVedder, N., Gercke, P., Lautenschlager, N., Brunn, T., Lange, T., Schieb, J., Vetter, C., van Geffen, C., & Kolahian, S. (2025) · The FASEB Journal · doi:10.1096/fj.202500312rr · Cited by 2
Acosta, R. J., McIntyre, D., Murray, J. C., Anagnostou, V., Brahmer, J. R., Meisel, A., Sezer, A., Gogishvili, M., Melkadze, T., Baramidze, A., et al. (2025) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2025.100959 · Cited by 2
Meng, X. M., Zhang, Y., Xu, H., Zhang, Y., He, H., Ma, J., & Zhang, X. (2025) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-025-06315-6 · Cited by 2
“However, in the tumor microenvironment, the immunosuppressive properties of MDSCs facilitate immune escape and disease progression (Li et al. 2021; Ostrand-Rosenberg and Fenselau 2018; Santibanez 2025).”
Yokota, S., Fujii, W., Motegi, T., Komori, M., Nishi, R., CHAMBERS, J. K., Uchida, K., Yonezawa, T., Momoi, Y., & Maeda, S. (2025) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2025.111019 · Cited by 2
Cadenas-Garrido, P., García‐Serna, A. M., Parrado, A., Martínez-García, J., Herrera-Suarez, M., Cánovas, M., Puente, T. D. D., Saceda, M., Pelegrín, P., Díaz-Carrasco, M. S., et al. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-02653-1 · Cited by 2
“In contrast, other researchers have reported that IL-8 and other molecules can also support tumor growth by recruiting greater numbers of infiltrating immune suppressive cells, which blocks the antitumor efficacy of cytotoxic T cells, to the TME [29, 30].”
Feng, Y., Wang, Y., Li, X., Wang, Y., & Zhang, M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1810065 · Cited by 3
“TAMs and MDSCs contribute to immune suppression by expressing PD-L1, TIM-3, and VISTA, which further inhibit effector T cell activity (153, 171).”
Liu, M. D., Dong, Y., Guan, Q., Wang, J., Shi, Q., Lin, R., Zhang, M., Fu, D., Cheng, S., Xu, P. P., et al. (2026) · Journal of Extracellular Vesicles · doi:10.1002/jev2.70309 · Cited by 2
Targeting cancer-associated fibroblasts in immunotherapy
Kim, D., Wu, Y., & Oh, Y. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85781-9.00007-5 · Cited by 3
Local immunotherapy of cancer and metastasis
Kwon, S., & Yeo, Y. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85781-9.00018-x · Cited by 2
Alpha-Fetoprotein Binds Toxins and Can Be Used to Treat Cancer
Pak, V. N. (2022) · Medical Research Archives · doi:10.18103/mra.v10i10.3236 · Cited by 2
CD8+ T Cell‐Mediated Therapeutic Antitumor Effect of an Herbal Mixture Containing Ganoderma lucidum
Takaku, S., Shimizu, M., & Morita, R. (2023) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2023/9630816 · Cited by 2
Liu, Y.-S., Wang, J., Jin, G., Hu, M.-H., & Wang, X. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25010663 · Cited by 2
Daifuku, R., Zhang, Y., Wang, J., & Gu, Q. (2024) · Translational Medicine Communications · doi:10.1186/s41231-024-00161-3 · Cited by 2
“(3 ) M-MDSC were significantly decreased with a trend towards a decrease in PMN-MDSC, suggesting a decrease in the likelihood of tumor immune escape [29].”
BackgroundInverso, D., Tacconi, C., Ranucci, S., & Giovanni, M. D. (2024) · European Journal of Immunology · doi:10.1002/eji.202350870 · Cited by 2
“Intriguingly, tumors can also remotely regulate CXCL12 distribution in the bone marrow to boost the egress of MDSCs that accumulate within the TME and suppress anticancer immunity [59, 60].”
Wang, W., Cao, C., Pandian, V. D., Ye, H., Chen, H., & Zhang, L. (2025) · Science Advances · doi:10.1126/sciadv.ads3728 · Cited by 3
“Murine Mo-MDSCs and PMN-MDCSs are defined as CD11b + Ly6C hi Ly6G − and CD11b + Ly6C lo Ly6G + cells, respectively, and their human counterparts are defined as CD11b + CD14 + HLA-DR - /lo CD15 − and CD11b + CD14 − HLA-DR - /lo CD15 + cells ( 3 , 4 ).”
Yamamoto, M., Horie, I., Isohama, Y., & Tsukimoto, M. (2020) · BPB Reports · doi:10.1248/bpbreports.3.2_70 · Cited by 2
Shen, H., Zhang, Y., Kramer, E. D., Katsuta, E., Wan, Y., Chen, Y., Wang, J., Zhang, Y., Matsuzaki, J., Frangou, C. G., et al. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-022-00502-0 · Cited by 2
“MDSCs are a heterogeneous population of largely immature myeloid cells that have potent immune suppressive activity [29, 30].”
BackgroundLin, L., Xu, S., Peng, F., Jin, H., & Xiao, F. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/6157385 · Cited by 2
The Possible Drug for Cancer and Metastasis Prevention
Pak, V. N. (2022) · Future Drug Discovery · doi:10.4155/fdd-2022-0008 · Cited by 2
Evaluation The Role of CD33+ CD11b+ myeloid-derived Suppressor Cells in Patients With AML
Hamad, H., Shabeeb, Z., & Awad, M. M. (2022) · Journal of university of Anbar for pure science · doi:10.37652/juaps.2022.174817 · Cited by 1
Ma, J. A., Orbach, S. M., Griffin, K. V., Kang, K., Zhang, Y., Pereles, R. S., Schrack, I. A., Escalona, G., Jeruss, J. S., & Shea, L. D. (2025) · Molecular Oncology · doi:10.1002/1878-0261.70040 · Cited by 1
Population Analysis and Immunologic Landscape of Melanoma in People Living with HIV
Barger, L. N., Wang, D., Saravia, A. L., Mezzano, V., Ward, G., Loomis, C., Feldman, C., Tuluc, M., Seedor, R. S., Gaskill, P. J., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-3148 · Cited by 1
Swiecicki, P. L., Othus, M. K. D., Patel, S. P., Chae, Y. K., & Kurzrock, R. (2026) · Cancer · doi:10.1002/cncr.70374 · Cited by 1
B cells promote the growth and stem-like qualities of breast cancer cells in the bone marrow
Sasaki, S., Wahyuniputri, R. F., Tanabe, Y., Zhou, Y., Terashima, Y., Sakurai, H., & Hayakawa, Y. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.154138 · Cited by 1
Retinoic acid–driven expansion of CD16hiCD177+ neutrophils mediates steroid-resistant GI-GVHD
Liang, W., Xu, D., Zhang, L. F., Qu, Y., Li, L., Zhong, K., Meng, Y., Zhu, J., Wang, S., Tan, L., et al. (2026) · Blood · doi:10.1182/blood.2025032193 · Cited by 1
Evdokimova, V. E., Ruzanov, P., Gassmann, H., Hung, M., Zhang, Z., Ribeiro, A. S., Khoshgoo, N., Zheng, S., Pachva, M. C., Ringwalt, E. M., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117708 · Cited by 1
Metabolic inflammation, obesity, and cancer
Alzaïd, F., Blériot, C., Anagnostopoulos, G., Chakarov, S., Venteclef, N., & Ginhoux, F. (2026) · Immunity · doi:10.1016/j.immuni.2026.07.020 · Cited by 1
Neelam, S., Mellon, J., Wilkerson, A., & Niederkorn, J. Y. (2019) · Melanoma Research · doi:10.1097/cmr.0000000000000614 · Cited by 1
Tracking Biodistribution of Myeloid-Derived Cells in Murine Models of Breast Cancer
Li, J., Mai, J., Hinkle, L. E., Lin, D., Zhang, J., Liu, X., Ramirez, M., Zu, Y., Lokesh, G. L.-R., Volk, D. E., et al. (2019) · Genes · doi:10.3390/genes10040297 · Cited by 1
[Mechanism of Xiaowugui decoction for treating collagen-induced arthritis in mice].
Shan, W., Zhu, X., Qi, J., Hu, F., Li, C., & Nie, X. (2020) · PubMed · doi:10.12122/j.issn.1673-4254.2020.11.23 · Cited by 1
Introduction: An Overview of Host-Directed Therapies for Tuberculosis
Frank, D. J., & Mahon, R. N. (2020) · Springer eBooks · doi:10.1007/978-3-030-56905-1_1 · Cited by 1
Checkpoint inhibition in the fight against cancer: NK cells have some to say in it
Sordo‐Bahamonde, C., Lorenzo‐Herrero, S., González, A. P., & Gonzalez, S. R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-824375-6.00013-8 · Cited by 1
Waeckel, L., Li, G., Anne-Emmanuelle, B., & Lambert, C. (2021) · Archives of Pathology and Clinical Research · doi:10.29328/journal.apcr.1001022 · Cited by 1
“FCM also helps in characterizing anti-tumor immunity, https://www.heighpubs.org/hjpcr 013https://doi.org/10.29328/journal.apcr.1001022 measuring TIL and TAM in iltrate [28-31] and detecting eventual immunosuppressive cells like myeloid-derived suppressor cells (MDSC) [32].”
InfluentialIntroduction to the Tumor Microenvironment
Witz, I. P., & Izraely, S. (2022) · Royal Society of Chemistry eBooks · doi:10.1039/9781839166013-00011 · Cited by 1
Tumor-Associated Myeloid Cells in Cancer Progression
Gulić, T., Silva-Gomes, R., Davoudian, S., Sironi, M., Allavena, P., Mantovani, A., & Bottazzi, B. (2020) · Springer eBooks · doi:10.1007/978-3-030-30845-2_3 · Cited by 1
The Role of miR-155 in Myeloid cells during Experimental Autoimmune Encephalomyelitis
Lyons, V. G. (2020) · Arrow@dit (Dublin Institute of Technology) · Cited by 1
Rinchai, D., Verzoni, E., Huber, V., Cova, A., Squarcina, P., Cecco, L. D., de Braud, F., Ratta, R., Dugo, M., Lalli, L., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.01.071613 · Cited by 2
Effects of Exercise on Myeloid-Derived Suppressor Cell-Related Tumor Progression and Metastasis
Garritson, J. D. (2020) · Scholarship & Creative Works - Digital UNC a service of University Libraries (University of Northern Colorado) · Cited by 1
Sidiropoulos, D. N., Rafie, C. I., Christmas, B. J., Davis-Marcisak, E. F., Sharma, G., Bigelow, E., Gupta, A. K., Yegnasubramanian, S., Stearns, V., Connolly, R. M., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.29.428708 · Cited by 1
“MDSCs accumulate in the TME and interfere with anti-tumor immune responses (Ostrand-Rosenberg et al. 2018).”
BackgroundOstrand‐Rosenberg, S. (2021) · Cellular Immunology · doi:10.1016/j.cellimm.2021.104374 · Cited by 2
Self-citationMyeloid-Derived Suppressor Cells in Cancer
Jaya, F. N. M., & Gabrilovich, D. I. (2024) · Elsevier eBooks · doi:10.1016/b978-0-128-24465-4.00087-9 · Cited by 1
Rodhouse, C., Barrios, E. L., Zeumer-Spataro, L., Balzano, L., Wu, R., Yu, X., Tian, G., Brant, J. O., Gauthier, M. L., Chen, J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.16.694726 · Cited by 2
Weppler, A. M., Lau, P. K. H., & McArthur, G. A. (2019) · Springer eBooks · doi:10.1007/978-3-319-46029-1_39-1
TGFβ Causes Postoperative Natural Killer Cell Paralysis Through mTOR Inhibition
Market, M. (2020) · uO Research (University of Ottawa) · doi:10.20381/ruor-25171
Immunological Features of Melanoma: Clinical Implications in the Era of New Therapies
Rivoltini, L., Cova, A., & Squarcina, P. (2021) · Springer eBooks · doi:10.1007/978-3-030-64009-5_4
Characteristics and therapy of advanced cancer diseases
Taghizadeh, H. (2021)
Stromal modulation strategies to improve immunotherapy response in cancer
Shi, K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-90949-5.00008-5
Khudovekova, A. S., Rudenko, Y. А., & Ae, D. (2021) · Oncohematology · doi:10.17650/1818-8346-2021-16-3-26-32
“Уровень Тreg возрастает в микроокружении костного мозга при про грессии из MGUS в ММ [20].”
Cancer Treatment with Oncoshuttle
Pak, V. N. (2021) · Cancer Science & Research · doi:10.33425/2639-8478.1071
“In addition to embryo cells, AFPmediated nutrients delivery to AFPR-positive myeloid-derived suppressor cells (MDSCs) potentiates the latter ability to suppress the mother’s immune system and prevent embryo rejection [5].”
BackgroundHsieh, C., Lin, C., Chiang, M., Chang, Y.-L., He, J.-T., & Hung, C. (2021) · Research Square · doi:10.21203/rs.3.rs-829410/v1
Weppler, A. M., Lau, P. K. H., & McArthur, G. A. (2020) · Springer eBooks · doi:10.1007/978-3-030-05070-2_39
Lim, C. L., & Lin, V. C. L. (2021) · Research Square · doi:10.21203/rs.3.rs-208162/v1
Japanese Kampo Medicine Juzentaihoto Improves Antiviral Cellular Immunity in Tumour-Bearing Hosts
Takaku, S., Shimizu, M., & Morita, R. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/6122955
“A recent study revealed that MDSCs are a major obstacle to antitumour immunity and numerous immunotherapies [36].”
BackgroundBiomarkers for Monitoring the Immunotherapy Response to Cancer
Mohebalizadeh, M., & Rezaei, N. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_131-1
Yang, B., Li, X., Fu, Y., Guo, E., Ye, Y., Li, F., Liu, S., Xiao, R., Liu, C., Lu, F., et al. (2023) · doi:10.1158/0008-5472.c.6512709.v1
Sheldon, H., Bridges, E., Silva, I., Masiero, M., Favara, D. M., Wang, D., Leek, R., Snell, C. E., Roxanis, I., Kreuzer, M., et al. (2023) · doi:10.1158/1541-7786.c.6545234
Shaul, M. E., Zlotnik, A., Tidhar, E., Schwartz, A., Arpinati, L., Kaisar-Iluz, N., Mahroum, S., Mishalian, I., & Fridlender, Z. G. (2023) · doi:10.1158/2326-6066.c.6550251.v1
Immunotherapeutic Targeting of AML
Motabi, I., Alahmari, B., & DiPersio, J. F. (2023) · Springer eBooks · doi:10.1007/978-981-99-3810-0_15
Yao, Y., Zhan, R., Gong, C., Lv, J., & Lu, X. (2023) · Medicine · doi:10.1097/md.0000000000034656
Taniura, T., Ishitobi, K., Hidaka, M., & Harada, M. (2023) · Microbiology and Immunology · doi:10.1111/1348-0421.13101
“14 Although MDSCs and Tregs are representative immuno-suppressive cells that can hinder antitumor T ‐ cell immunity in tumor ‐ bearing hosts, 3 – 7 5 ‐ FU and CP diminish MDSC and Treg expression in cancer ‐ bearing hosts, respectively.”
BackgroundStudstill, C. J. (2020) · MOspace Institutional Repository (University of Missouri) · doi:10.32469/10355/88918
Joseph, E. L. M. (2019) · theses.fr (ABES) · doi:10.70675/bba1a27bz36bdz488cza60azf58fa2e47702
Reyes-Martínez, P., Díaz, E. S., Bravo‐Cuéllar, A., Sandoval-Tamayo, J. L., Sánchez-Villaseñor, G., & Ortiz‐Lazareno, P. C. (2024) · Boletín del Colegio Mexicano de Urología · doi:10.24875/bcmu.23000019
Tumor microenvironment and chemoresistance
Asare-Werehene, M., & Tsang, B. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-824040-3.00001-7
Amin, T., Jerin, N., Fakruddin, M., Jime, J. S., Bulbul, N., Siddiqi, S. S., & Islam, S. M. B. U. (2024) · Journal of Angiotherapy · doi:10.25163/angiotherapy.869685
Etude du microenvironnement tumoral des cancers de l’ovaire en fonction de l’instabilité génomique
Fumet, J.-D. (2022) · theses.fr (ABES) · doi:10.70675/ed5879b6z2c3az44f3z99cbz8466ad6dca12
Васильевич, Б. Е., Aristova, T. A., Denisova, V. V., & Ushakova, G. Y. (2024) · Medical Immunology (Russia) · doi:10.15789/1563-0625-eog-16683
Regulation of myeloid-derived suppressor cells by glutamate
Tachibana, M. (2025) · Folia Pharmacologica Japonica · doi:10.1254/fpj.25009
Miguel, R. D. V., Charek, J. G., Fan, S., Coble, D. J., Calla, N. E. Q., & Cherpes, T. L. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.25.666778
Biomarkers for Monitoring the Immunotherapy Response to Cancer
Mohebalizadeh, M., & Rezaei, N. (2025) · Springer eBooks · doi:10.1007/978-3-032-00763-6_131
Daifuku, R., Zhang, Y., Wang, J., & Gu, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26669574
O’Leary, K. A., Bates, A. M., Jin, W. J., Burkel, B. M., Sriramaneni, R. N., Emma, S. E., Nystuen, E. J., Sumiec, E. G., Ponik, S. M., Morris, Z. S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26596985
Zhang, Q., Yu, T., Tan, H., & Shi, H. (2024) · Figshare · doi:10.6084/m9.figshare.25824754
Regulation of tumor progression by myeloid cells
Jaya, F. N. M., & Gabrilovich, D. I. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-14064-8.00038-2
Hao, S., Xu, S., Li, L., Li, Y., Zhao, M., Chen, J., Zhu, S., Xie, Y., Jiang, H., Zhu, J., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21400335
Lim, C. L., & Lin, V. C.-L. (2021) · Figshare · doi:10.6084/m9.figshare.16608976
O’Leary, K. A., Bates, A. M., Jin, W. J., Burkel, B. M., Sriramaneni, R. N., Emma, S. E., Nystuen, E. J., Sumiec, E. G., Ponik, S. M., Morris, Z. S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26596988
Daifuku, R., Zhang, Y., Wang, J., & Gu, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26669577
Caracterización de células mieloides inmunosupresoras en un modelo murino de tumorigénesis
Sanz Carrasco, N., & Aguiló Anento, J. I. (2020) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
AlRammah, T., Wu, R., Chida, K., Kawashima, K., Hakamada, K., Ishikawa, T., Ebos, J. M. L., & Takabe, K. (2026) · World Journal of Oncology · doi:10.14740/wjon2708
“MDSCs are a heterogeneous population of immature myeloid cells that have potent immune suppressive activity [62].”
He, Y., & Yeo, Y. (2026) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.70052
“Many chemotherapeutic agents induce immunogenic cell death, causing the release of high mobility group B1 (HMGB1), a damage-associated molecular pattern (DAMP) (Kwon et al. 2024), which can promote MDSC generation (Ostrand-Rosenberg and Fenselau 2018).”
The role of myeloid-derived suppressor cells in Sjögren's disease
Jin, L., Yang, C., Gan, J., Wan, Z., Liu, Y., Wong, V. K. W., Li, C., & Wang, Y. (2026) · Autoimmunity Reviews · doi:10.1016/j.autrev.2026.104051
Simonneau, M. (2018) · theses.fr (ABES) · doi:10.70675/34bc0b41z17a7z49e0zb6c5zd874a4c8cbeb · Cited by 1
Jacquemin, G. (2021) · theses.fr (ABES) · doi:10.70675/eb1fecbaz8065z42ebzb918ze92070a1ff72
Metadata
- Authors
- Ostrand-Rosenberg, S., & Fenselau, C.
- Affiliations
- Department of Biological Sciences, University of Maryland Baltimore County , Baltimore, MD 21250
- University of Maryland, College Park (US)
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-01
- Volume
- 200
- Issue
- 2
- Pages
- 422-431
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- PMC
- PMC5765878
- OpenAlex
- W2783633531
- Cited by
- 509
- References
- 135
- Citations by year
- 2026: 34 · 2025: 42 · 2024: 44 · 2023: 61 · 2022: 71 · 2021: 117 · 2020: 80 · 2019: 39 · 2018: 21
- FWCI
- 6.57
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Maryland Shared Open Access Repository (USMAI Consortium) (submittedVersion)
- Digital Repository at the University of Maryland (University of Maryland College Park)
- Funders
- National Institutes of Health (1s10od019938-01, RO1 GM021248)
- National Cancer Institute (R01CA084232, R01CA115880)
- National Institute of General Medical Sciences (R01GM021248)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- myeloid-derived suppressor cells, tumor immunosuppression, antitumor immunity, tumor microenvironment, pro-inflammatory mediators, neutrophils, cancer immunotherapy resistance, tumor progression
- MeSH terms
- Myeloid-Derived Suppressor Cells, Animals, Humans, Neoplasms, Phenotype, Cytokines, Disease Progression, Inflammation Mediators, Immunomodulation, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.